OceanTrans Biotechnology

OceanTrans Biotechnology is a clinical-stage biopharmaceutical company specialized in the oral delivery of macromolecular drugs, including peptides and proteins. The company utilizes its proprietary "Trans-Biologics" platform, which leverages peptide-mediated transcytosis to transport biological drugs across the intestinal epithelial barrier into the bloodstream. This technology aims to replace traditional injections with oral formulations for chronic conditions, significantly improving patient compliance. OceanTrans is primarily focused on metabolic diseases, with a pipeline featuring oral GLP-1 receptor agonists and oral insulin. The company is headquartered in Shenzhen, China, and is supported by prominent venture capital investors.